Cases

Search for a case

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Cases

November 23, 2022

Metacrine, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Metacrine, Inc. (“Metacrine” or the “Company”) (NASDAQ:MTCR), in connection with the acquisition of the Company by Equillium, Inc. (“Equillium”)(NASDAQ: EQ). Under the terms of the merger agreement, Equillium will issue stock valued at a 25% premium over the net cash delivered at closing, which is estimated to be approximately $26 million.

Join Case →

November 21, 2022

Imago BioSciences, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Imago BioSciences, Inc. (“Imago” or the “Company”) (NASDAQ: IMGO), in connection with the tender offer for the Company by a subsidiary of Merck & Co., Inc. (NYSE: MRK). Under the tender offer terms, the Company’s shareholders will receive $36.00 in cash for each share of Imago common stock owned.

Join Case →

November 18, 2022

Surrey Bancorp Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Surrey Bancorp (“Surrey” or the “Company”) (OTCPK:SRYB) in connection with the proposed acquisition of the Company by First Community Bankshares, Inc. (“First Community”) (NASDAQ: FCBC). Under the merger agreement, the Company’s shareholders will receive 0.7159 shares of First Community common stock for each Surrey share owned, representing implied per-share consideration of $27.51 based upon First Community’s November 17, 2022 closing price of $38.43.

Join Case →

November 17, 2022

Elevate Credit, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Elevate Credit, Inc. (“Elevate” or the “Company”) (NYSE: ELVT), in connection with the proposed acquisition of the Company by an affiliate of Park Cities Asset Management LLC. Under the terms of the merger agreement, the Company’s shareholders will receive $1.87 in cash for each share of Elevate common stock owned.

Join Case →

November 14, 2022

Washington Federal, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Washington Federal, Inc. (“Washington Federal” or the “Company”) (NASDAQ: WAFD), in connection with its takeover of Luther Burbank Corporation (NASDAQ: LBC).

Join Case →

November 14, 2022

Luther Burbank Corporation Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Luther Burbank Corporation (“Luther Burbank” or the “Company”) (NASDAQ: LBC) in connection with its takeover by Washington Federal, Inc. (“Washington Federal”) (NASDAQ: WAFD). Under the merger agreement, the Company’s shareholders will receive 0.3353 shares of Washington Federal common stock for each Luther Burbank share, representing implied per-share consideration of $12.79 based upon Washington Federal’s November 11, 2022 closing price of $38.15.

Join Case →

November 14, 2022

Opiant Pharmaceuticals, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Opiant Pharmaceuticals, Inc. (“Opiant” or the “Company”) (NASDAQ: OPNT), in connection with its takeover by Indivior PLC. Under the terms of the merger agreement, shareholders will receive $20.00 cash for each Opiant share, plus up to $8.00 per share in contingent value rights (“CVRs”) if revenue milestones are achieved by Opiant's lead asset (OPNT003) in the seven years after the U.S. commercial launch of OPNT003.

Join Case →

November 14, 2022

Applied Genetic Technologies Corporation Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Applied Genetic Technologies Corporation (“Applied Genetic” or the “Company”) (NASDAQ: AGTC), in connection with the proposed acquisition of the Company via tender offer. Under the tender offer, the Company’s shareholders will receive $0.34 in cash for each share of Applied Genetic common stock owned, plus one non-tradeable contingent value right (“CVR”).

Join Case →

November 7, 2022

Oyster Point Pharma, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Oyster Point Pharma, Inc. (“Oyster Point” or the “Company”) (NASDAQ: OYST), in connection with the proposed acquisition of the Company by Viatris Inc. (NASDAQ: VTRS) via tender offer. Under the terms of the merger agreement, the Company’s shareholders will receive $11.00 in cash for each share of Oyster Point common stock owned, plus a contingent value right (“CVR”) representing the right to receive a potential cash payment of up to $2.00 per share.

Join Case →

We will fight for you and have your back no matter what. Join the tens of thousands of people we’ve helped.

Cases

Search for a case

Cases

Metacrine, Inc. Investigation

Imago BioSciences, Inc. Investigation

Surrey Bancorp Investigation

Elevate Credit, Inc. Investigation

Washington Federal, Inc. Investigation

Luther Burbank Corporation Investigation

Opiant Pharmaceuticals, Inc. Investigation

Applied Genetic Technologies Corporation Investigation

Oyster Point Pharma, Inc. Investigation

Where to find us?

new york

california

georgia

NEW JERSEY